Scrip
>>R&D

Global CRISPR Revolution Gathers Pace, Raising Hopes – And Concerns

24 Nov 2017

• By Sten Stovall

CRISPR technology was invented just five years ago but is so accurate, versatile, easy to use, and inexpensive that it has spread quickly through biology laboratories, giving researchers new tools to interrogate biology and make precise alterations to an organism’s genetic material, offering its potential use in a wide array of therapies.

DNA — CRISPR-Cas9 Gene Editing Revolution Is Just Starting • Source: Shutterstock

CRISPR and similar gene editing technologies are giving researchers new tools to interrogate biology and make precise alterations to an organism’s genetic material. The medical and commercial promise emerging from this disruptive technology is huge.

But the speed with which CRISPR techniques are being developed and applied has made mainstream news and led many policymakers and stakeholders to voice worries about whether appropriate systems are...

Available now…

more exclusive Scrip 100 features and the full Scrip 100 2018 review

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.